Cargando…
Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961623/ https://www.ncbi.nlm.nih.gov/pubmed/29844731 http://dx.doi.org/10.1016/j.jsps.2018.01.014 |
_version_ | 1783324750365327360 |
---|---|
author | Mabrouk, Mostafa Beherei, Hanan H. ElShebiney, Shaimaa Tanaka, Masaru |
author_facet | Mabrouk, Mostafa Beherei, Hanan H. ElShebiney, Shaimaa Tanaka, Masaru |
author_sort | Mabrouk, Mostafa |
collection | PubMed |
description | This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with dipping technique with β-cyclodextrin. The chemical integrity and surface morphology of the ribbons were confirmed using FTIR and SEM coupled with EDX. In addition, thermodynamic behavior of the fabricated ribbons was investigated using DSC/TGA. Tramadol loading into PCL ribbons, biodegradation of ribbons and tramadol release kinetics were studied in PBS.The results revealed that the formulated composition did not affect the chemical integrity of the drug. Furthermore, SEM/EDX confirmed the inclusion of tramadol into the PCL matrix in homogenous distribution pattern without any observation of porous structure. The particle size of loaded tramadol was found to be in the range of (2–4 nm). The formulated composition did not affect the chemical integrity of the drug and should be further investigated for bioavailability. Tramadol exhibited controlled release behavior from PCL ribbons up to 45 days governed mainly by diffusion mechanism. The fabricated ribbons have a great potentiality to be implemented in the long term subcutaneous delivery of tramadol. |
format | Online Article Text |
id | pubmed-5961623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-59616232018-05-29 Newly developed controlled release subcutaneous formulation for tramadol hydrochloride Mabrouk, Mostafa Beherei, Hanan H. ElShebiney, Shaimaa Tanaka, Masaru Saudi Pharm J Original Article This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with dipping technique with β-cyclodextrin. The chemical integrity and surface morphology of the ribbons were confirmed using FTIR and SEM coupled with EDX. In addition, thermodynamic behavior of the fabricated ribbons was investigated using DSC/TGA. Tramadol loading into PCL ribbons, biodegradation of ribbons and tramadol release kinetics were studied in PBS.The results revealed that the formulated composition did not affect the chemical integrity of the drug. Furthermore, SEM/EDX confirmed the inclusion of tramadol into the PCL matrix in homogenous distribution pattern without any observation of porous structure. The particle size of loaded tramadol was found to be in the range of (2–4 nm). The formulated composition did not affect the chemical integrity of the drug and should be further investigated for bioavailability. Tramadol exhibited controlled release behavior from PCL ribbons up to 45 days governed mainly by diffusion mechanism. The fabricated ribbons have a great potentiality to be implemented in the long term subcutaneous delivery of tramadol. Elsevier 2018-05 2018-01-31 /pmc/articles/PMC5961623/ /pubmed/29844731 http://dx.doi.org/10.1016/j.jsps.2018.01.014 Text en © 2018 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Mabrouk, Mostafa Beherei, Hanan H. ElShebiney, Shaimaa Tanaka, Masaru Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title_full | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title_fullStr | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title_full_unstemmed | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title_short | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
title_sort | newly developed controlled release subcutaneous formulation for tramadol hydrochloride |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961623/ https://www.ncbi.nlm.nih.gov/pubmed/29844731 http://dx.doi.org/10.1016/j.jsps.2018.01.014 |
work_keys_str_mv | AT mabroukmostafa newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride AT behereihananh newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride AT elshebineyshaimaa newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride AT tanakamasaru newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride |